ClinicalTrials.gg
CompletedNCT03930732BOREASUpdated Feb 28, 2024Results posted

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

A Phase 3 interventional study of Dupilumab SAR231893 and Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Completed at 275 sites in 24 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
939
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.

Enrollment
6th of 12
939 · median 937
Started
2019
the only one that year
Phase 3
8 of 15
3 open now
Registered
2nd of 15
by date

Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 8 in phase 3, and was the 2nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by

  • Annualized rate of acute moderate and severe COPD exacerbation (AECOPD)

Secondary Objectives:

To evaluate the effect of dupilumab administered every 2 weeks on

  • Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo
  • Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ)
  • Pre-bronchodilator FEV1 over 52 weeks compared to placebo
  • Lung function assessments
  • Moderate and severe COPD exacerbations
  • To evaluate safety and tolerability
  • To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies (ADA)
Read the detailed description

Approximately 68 weeks including a 4-week screening period, a 52-week treatment period, and 12 weeks of follow-up.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a physician diagnosis of who met the following criteria at screening:

    • Current or former smokers with a smoking history of ≥10 pack-years.
    • Moderate-to-severe COPD (post-bronchodilator / forced vital capacity [FVC] ratio \<0.70 and post-bronchodilator FEV1 % predicted >30% and ≤70%).
    • Medical Research Council (MRC) Dyspnea Scale grade ≥2.
    • Patient-reported history of signs and symptoms of chronic bronchitis (chronic productive cough) for 3 months in the year up to screening in the absence of other known causes of chronic cough.
    • Documented history of high exacerbation risk defined as exacerbation history of ≥2 moderate or ≥1 severe within the year prior to inclusion. At least one exacerbation should have occurred while the patient was taking inhaled (ICS)/long acting beta agonist (LABA)/long acting muscarinic antagonist (LAMA) (or LABA/LAMA if ICS is ). Moderate exacerbations were recorded by the investigator and defined as acute exacerbation of COPD (AECOPD) that required either systemic corticosteroids (intramuscular, intravenous, or oral) and/or antibiotics. One of the two required moderate exacerbations had to require the use of systemic corticosteroids. Severe exacerbations were recorded by the investigator and defined as AECOPD requiring hospitalization or observation >24 hours in emergency department/urgent care facility.
    • Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to Visit 1; Double therapy (LABA + LAMA) allowed if ICS was contraindicated.
  • Evidence of Type 2 inflammation: Patients with blood eosinophils ≥300 cells/microliter at Visit 1.

Exclusion criteria

Exclusion criteria:

  • diagnosis for less than 12 months prior to randomization.
  • A current diagnosis of asthma or history of asthma according to the 2018 Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.
  • Significant pulmonary disease other than COPD (e.g., lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome etc) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
  • Cor pulmonale, evidence of right cardiac failure.
  • Treatment with oxygen of more than 12 hours per day.
  • Hypercapnia requiring Bi-level ventilation.
  • AECOPD as defined in inclusion criteria within 4 weeks prior to screening, or during the screening period.
  • Respiratory tract infection within 4 weeks prior to screening, or during the screening period.
  • History of, or planned pneumonectomy or lung volume reduction surgery. Patients who were participating in the acute phase of a pulmonary rehabilitation program, ie, who started rehabilitation \<4 weeks prior to screening (Note: patients in the maintenance phase of a rehabilitation program could be included).
  • Diagnosis of α-1 anti-trypsin deficiency.

The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
939 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Participants received dupilumab 300 mg administered as SC injections q2w up to a maximum of 52 weeks (last dose administered at Week 50, EOT visit occurred 2 weeks after last administration of treatment i.e., at Week 52).

    Drug: Dupilumab SAR231893 · Drug: Inhaled Corticosteroid · Drug: Inhaled Long-Acting Beta Agonist · Drug: Inhaled Long-Acting Muscarinic Antagonist

  • Placebo comparator
    Placebo

    Participants received placebo matched to dupilumab 300 mg as subcutaneous (SC) injections q2w up to a maximum of 52 weeks (last dose administered at Week 50, end of treatment \[EOT\] visit occurred 2 weeks after last administration of treatment i.e., at Week 52).

    Drug: Inhaled Corticosteroid · Drug: Inhaled Long-Acting Beta Agonist · Drug: Inhaled Long-Acting Muscarinic Antagonist · Drug: Placebo

Interventions

  • Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

    Also known as: Dupixent

  • DrugInhaled Corticosteroid

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • DrugInhaled Long-Acting Beta Agonist

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • DrugInhaled Long-Acting Muscarinic Antagonist

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • DrugPlacebo

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period

    Moderate exacerbations were recorded by the Investigator and defined as acute exacerbation of COPD (AECOPD) that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.

    Time frame: Baseline (Day 1) to Week 52

Secondary outcomes

  1. Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Week 12

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to Week 12

  2. Change From Baseline in Pre-BD FEV1 at Week 52

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to Week 52

  3. Change From Baseline in Pre-BD FEV1 at Week 12 in Subgroup of Participants With Baseline Fractional Exhaled Nitric Oxide (FeNO) >=20 Parts Per Billion (Ppb)

    FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 milliliter per second (mL/s) and reported in ppb. This assessment was conducted prior to spirometry and following a fast of at least 1 hour.

    Time frame: Baseline (Day 1) to Week 12

  4. Change From Baseline in Pre-BD FEV1 at Week 52 in Subgroup of Participants With Baseline FeNO >=20 Ppb

    FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/s and reported in ppb. This assessment was conducted prior to spirometry and following a fast of at least 1 hour.

    Time frame: Baseline (Day 1) to Week 52

  5. Change From Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) Total Score at Week 52

    The SGRQ was a 50-item self-administered questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation and rated on electronic diary. Scores by dimension were calculated for 3 domains: symptoms, activity and impacts (psycho-social) as well as a total score. Global and domain scores range from 0 to 100, with 100 representing the worst possible health status and 0 indicating the best possible health status. Higher score indicates worse health status/heath related quality of life.

    Time frame: Baseline (Day 1) to Week 52

  6. Percentage of Participants With SGRQ Improvement >=4 Points at Week 52

    A responder was defined as a participant with improvement from baseline in SGRQ total score at Week 52 by \>=4 points. Participants with improvement \<4 points or with missing values were considered as non-responders. The percentage of participants who achieved a clinically meaningful response in SGRQ total score (reduction \[improvement\] by \>=4 points)/responders are reported.

    Time frame: Baseline (Day 1) to Week 52

  7. Change From Baseline in Evaluating Respiratory Symptoms (E-RS) in COPD (E-RS: COPD) RS-Total Score at Week 52

    The E-RS in COPD scale was a part of the exacerbations of chronic pulmonary disease tool (EXACT). It was a derivative instrument used to measure the effect of treatment on the severity of respiratory symptoms in stable COPD. E-RS: COPD RS-Total Score was derived based on weekly averages of daily assessed 11 respiratory symptom items contained in the 14-item EXACT questionnaire. The RS-Total score represented overall respiratory symptom severity, ranged from 0 to 40. Summation procedure was used to derive the three daily domain scores: 1). RS-Breathlessness (range 0-17), 2) RS-Cough and Sputum (score range 0-11), 3) RS-Chest Symptoms (score range 0-12). The higher the score, more severe were the symptoms.

    Time frame: Baseline (Day 1) to Week 52

  8. Annualized Rate of Moderate or Severe COPD Exacerbation Over the 52-Week Treatment Period in Subgroup of Participants With Baseline FeNO >=20 Ppb

    Moderate exacerbations were recorded by the Investigator and defined as AECOPD that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate among participants with baseline FeNO \>=20 ppb was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.

    Time frame: Baseline (Day 1) to Week 52

  9. Change From Baseline in Pre-BD FEV1 to Weeks 2, 4, 8, 24, 36 and 44

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to Weeks 2, 4, 8, 24, 36 and 44

  10. Change From Baseline in Post-BD FEV1 to Weeks 2, 4, 8, 12, 24, 36 and 52

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD FEV1 referred to the spirometry performed within 30 minutes after administration of bronchodilator.

    Time frame: Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36 and 52

  11. Change From Baseline in Pre-BD Forced Expiratory Flow at 25 Percent (%) to 75% (FEF 25-75%) of Forced Vital Capacity (FVC) to Weeks 2, 4, 8, 12, 24, 36, 44, and 52

    FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36, 44 and 52

  12. Change From Baseline in Post-BD FEF 25-75% to Weeks 2, 4, 8, 12, 24, 36 and 52

    FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36 and 52

  13. Annualized Rate of Severe COPD Exacerbations Over the 52-Week Treatment Period

    Moderate exacerbations were recorded by the Investigator and defined as AECOPD that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.

    Time frame: Baseline (Day 1) to Week 52

  14. Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period

    The time to first moderate or severe exacerbation was defined as date of the first event minus randomization date +1. The median time to first severe exacerbation was derived from Cox regression model. Moderate exacerbations events were recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days.

    Time frame: Baseline (Day 1) and up to Weeks 12, 24, 36 and 52

  15. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An Adverse Event (AE) was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TE period which was defined as the period from the time of first dose of study treatment until the last visit in the study. Serious adverse events (SAE) were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

    Time frame: TEAEs were collected from the time from the first administration of study treatment to the last administration of the study treatment + 98 days, up to 491 days

  16. Number of Participants With Anti-Drug Antibodies (ADA) to Dupilumab

    Number of participants with treatment-emergent response to dupilumab with peak post-baseline titers during the on-treatment period are reported. Treatment-emergent response was defined as a positive response in the ADA assay post first dose, when baseline results were negative or missing. Categories were based on titer values and included: low (Titer \<1000); moderate (1000\<=Titer\<=10,000); and high (Titer \>10,000). On-treatment period was defined as last study treatment administration plus 14 days; that is, Week 52.

    Time frame: Up to Week 52

07

Results

Posted Feb 28, 2024

Participant flow

The study was conducted at 275 centers in 24 countries. A total of 2599 participants were screened from 15 Apr 2019 to 12 Jan 2022, of which 1660 were screen failures due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestonePlaceboDupilumab 300 mg q2w
Started471468
Safety population470469
Completed434440
Not completed3728
Withdrew: Adverse event97
Withdrew: Poor compliance to protocol01
Withdrew: Withdrawal by subject2311
Withdrew: Other reason related to coronavirus disease-2019 (covid-19)01
Withdrew: Other reason not related to covid-1958

Outcome measures

PrimaryAnnualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period

Moderate exacerbations were recorded by the Investigator and defined as acute exacerbation of COPD (AECOPD) that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Number · exacerbation per participant-year
Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period
exacerbation per participant-yearPlaceboDupilumab 300 mg q2w
Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period1.01 (0.931 to 1.301)0.776 (0.645 to 0.934)
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · Negative binomial model · p = 0.0005 · Risk difference (rd): -0.324 · 95% CI -0.508 to -0.140Derived using delta method.
SecondaryChange From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Week 12

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · liters
Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Week 12
litersPlaceboDupilumab 300 mg q2w
Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Week 120.077 ± 0.0180.160 ± 0.018
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · MMRM model · p = <0.0001 (Threshold for significance at 0.049 level.) · Least square (ls) mean difference: 0.083 · 95% CI 0.042 to 0.125
SecondaryChange From Baseline in Pre-BD FEV1 at Week 52

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · liters
Change From Baseline in Pre-BD FEV1 at Week 52
litersPlaceboDupilumab 300 mg q2w
Change From Baseline in Pre-BD FEV1 at Week 520.070 ± 0.0190.153 ± 0.019
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · MMRM model · p = 0.0003 (Threshold for significance at 0.049 level.) · Ls mean difference: 0.083 · 95% CI 0.038 to 0.128
SecondaryChange From Baseline in Pre-BD FEV1 at Week 12 in Subgroup of Participants With Baseline Fractional Exhaled Nitric Oxide (FeNO) >=20 Parts Per Billion (Ppb)

FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 milliliter per second (mL/s) and reported in ppb. This assessment was conducted prior to spirometry and following a fast of at least 1 hour.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · liters
Change From Baseline in Pre-BD FEV1 at Week 12 in Subgroup of Participants With Baseline Fractional Exhaled Nitric Oxide (FeNO) >=20 Parts Per Billion (Ppb)
litersPlaceboDupilumab 300 mg q2w
Change From Baseline in Pre-BD FEV1 at Week 12 in Subgroup of Participants With Baseline Fractional Exhaled Nitric Oxide (FeNO) >=20 Parts Per Billion (Ppb)0.108 ± 0.0350.232 ± 0.034
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · MMRM model · p = 0.0022 (Threshold for significance at 0.049 level.) · Ls mean difference: 0.124 · 95% CI 0.045 to 0.203
SecondaryChange From Baseline in Pre-BD FEV1 at Week 52 in Subgroup of Participants With Baseline FeNO >=20 Ppb

FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/s and reported in ppb. This assessment was conducted prior to spirometry and following a fast of at least 1 hour.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · liters
Change From Baseline in Pre-BD FEV1 at Week 52 in Subgroup of Participants With Baseline FeNO >=20 Ppb
litersPlaceboDupilumab 300 mg q2w
Change From Baseline in Pre-BD FEV1 at Week 52 in Subgroup of Participants With Baseline FeNO >=20 Ppb0.120 ± 0.0370.247 ± 0.036
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · MMRM model · p = 0.0034 (Threshold for significance at 0.049 level.) · Ls mean difference: 0.127 · 95% CI 0.042 to 0.212
SecondaryChange From Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) Total Score at Week 52

The SGRQ was a 50-item self-administered questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation and rated on electronic diary. Scores by dimension were calculated for 3 domains: symptoms, activity and impacts (psycho-social) as well as a total score. Global and domain scores range from 0 to 100, with 100 representing the worst possible health status and 0 indicating the best possible health status. Higher score indicates worse health status/heath related quality of life.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
score on a scalePlaceboDupilumab 300 mg q2w
Change From Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) Total Score at Week 52-6.369 ± 0.816-9.732 ± 0.810
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · MMRM model · p = 0.0017 (Threshold for significance at 0.049 level.) · Ls mean difference: -3.363 · 95% CI -5.459 to -1.266
SecondaryPercentage of Participants With SGRQ Improvement >=4 Points at Week 52

A responder was defined as a participant with improvement from baseline in SGRQ total score at Week 52 by \>=4 points. Participants with improvement \<4 points or with missing values were considered as non-responders. The percentage of participants who achieved a clinically meaningful response in SGRQ total score (reduction \[improvement\] by \>=4 points)/responders are reported.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With SGRQ Improvement >=4 Points at Week 52
percentage of participantsPlaceboDupilumab 300 mg q2w
Percentage of Participants With SGRQ Improvement >=4 Points at Week 5243.151.5
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · Regression, Logistic · p = 0.0089 (Threshold for significance at 0.049 level.) · Odds ratio (or): 1.439 · 95% CI 1.096 to 1.890
SecondaryChange From Baseline in Evaluating Respiratory Symptoms (E-RS) in COPD (E-RS: COPD) RS-Total Score at Week 52

The E-RS in COPD scale was a part of the exacerbations of chronic pulmonary disease tool (EXACT). It was a derivative instrument used to measure the effect of treatment on the severity of respiratory symptoms in stable COPD. E-RS: COPD RS-Total Score was derived based on weekly averages of daily assessed 11 respiratory symptom items contained in the 14-item EXACT questionnaire. The RS-Total score represented overall respiratory symptom severity, ranged from 0 to 40. Summation procedure was used to derive the three daily domain scores: 1). RS-Breathlessness (range 0-17), 2) RS-Cough and Sputum (score range 0-11), 3) RS-Chest Symptoms (score range 0-12). The higher the score, more severe were the symptoms.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Evaluating Respiratory Symptoms (E-RS) in COPD (E-RS: COPD) RS-Total Score at Week 52
score on a scalePlaceboDupilumab 300 mg q2w
Change From Baseline in Evaluating Respiratory Symptoms (E-RS) in COPD (E-RS: COPD) RS-Total Score at Week 52-1.558 ± 0.256-2.694 ± 0.257
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · MMRM model · p = 0.0012 (Threshold for significance at 0.049 level.) · Ls mean difference: -1.137 · 95% CI -1.823 to -0.450
SecondaryAnnualized Rate of Moderate or Severe COPD Exacerbation Over the 52-Week Treatment Period in Subgroup of Participants With Baseline FeNO >=20 Ppb

Moderate exacerbations were recorded by the Investigator and defined as AECOPD that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate among participants with baseline FeNO \>=20 ppb was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Number · exacerbation per participant-year
Annualized Rate of Moderate or Severe COPD Exacerbation Over the 52-Week Treatment Period in Subgroup of Participants With Baseline FeNO >=20 Ppb
exacerbation per participant-yearPlaceboDupilumab 300 mg q2w
Annualized Rate of Moderate or Severe COPD Exacerbation Over the 52-Week Treatment Period in Subgroup of Participants With Baseline FeNO >=20 Ppb1.117 (0.831 to 1.502)0.699 (0.510 to 0.958)
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w · Negative binomial model · p = 0.0052 (Threshold for significance at 0.049 level.) · Risk difference (rd): -0.418 · 95% CI -0.728 to -0.109Derived using delta method.
SecondaryChange From Baseline in Pre-BD FEV1 to Weeks 2, 4, 8, 24, 36 and 44

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

Time frame:
Baseline (Day 1) to Weeks 2, 4, 8, 24, 36 and 44
Reported as:
Least squares mean · liters
Change From Baseline in Pre-BD FEV1 to Weeks 2, 4, 8, 24, 36 and 44
litersPlaceboDupilumab 300 mg q2w
Week 20.075 ± 0.0170.159 ± 0.017
Week 40.069 ± 0.0170.163 ± 0.017
Week 80.069 ± 0.0170.149 ± 0.017
Week 240.068 ± 0.0180.170 ± 0.018
Week 360.072 ± 0.0180.155 ± 0.018
Week 440.089 ± 0.0190.176 ± 0.019
SecondaryChange From Baseline in Post-BD FEV1 to Weeks 2, 4, 8, 12, 24, 36 and 52

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD FEV1 referred to the spirometry performed within 30 minutes after administration of bronchodilator.

Time frame:
Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36 and 52
Reported as:
Least squares mean · liters
Change From Baseline in Post-BD FEV1 to Weeks 2, 4, 8, 12, 24, 36 and 52
litersPlaceboDupilumab 300 mg q2w
Week 20.071 ± 0.0170.158 ± 0.017
Week 40.080 ± 0.0170.158 ± 0.017
Week 80.077 ± 0.0180.153 ± 0.018
Week 120.084 ± 0.0180.156 ± 0.018
Week 240.072 ± 0.0190.169 ± 0.019
Week 360.072 ± 0.0190.155 ± 0.019
Week 520.058 ± 0.0190.138 ± 0.019
SecondaryChange From Baseline in Pre-BD Forced Expiratory Flow at 25 Percent (%) to 75% (FEF 25-75%) of Forced Vital Capacity (FVC) to Weeks 2, 4, 8, 12, 24, 36, 44, and 52

FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

Time frame:
Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36, 44 and 52
Reported as:
Least squares mean · liters/second
Change From Baseline in Pre-BD Forced Expiratory Flow at 25 Percent (%) to 75% (FEF 25-75%) of Forced Vital Capacity (FVC) to Weeks 2, 4, 8, 12, 24, 36, 44, and 52
liters/secondPlaceboDupilumab 300 mg q2w
Week 20.065 ± 0.0160.110 ± 0.016
Week 40.066 ± 0.0150.115 ± 0.015
Week 80.069 ± 0.0160.114 ± 0.016
Week 120.076 ± 0.0160.137 ± 0.016
Week 240.080 ± 0.0170.142 ± 0.017
Week 360.087 ± 0.0170.132 ± 0.017
Week 440.091 ± 0.0170.162 ± 0.017
Week 520.088 ± 0.0170.135 ± 0.017
SecondaryChange From Baseline in Post-BD FEF 25-75% to Weeks 2, 4, 8, 12, 24, 36 and 52

FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Spirometry was performed after a wash out period of bronchodilators according to their action duration.

Time frame:
Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36 and 52
Reported as:
Least squares mean · liters/second
Change From Baseline in Post-BD FEF 25-75% to Weeks 2, 4, 8, 12, 24, 36 and 52
liters/secondPlaceboDupilumab 300 mg q2w
Week 20.074 ± 0.0170.135 ± 0.017
Week 40.087 ± 0.0170.144 ± 0.017
Week 80.083 ± 0.0170.144 ± 0.017
Week 120.089 ± 0.0180.161 ± 0.018
Week 240.093 ± 0.0190.169 ± 0.019
Week 360.093 ± 0.0190.161 ± 0.018
Week 520.093 ± 0.0190.153 ± 0.019
SecondaryAnnualized Rate of Severe COPD Exacerbations Over the 52-Week Treatment Period

Moderate exacerbations were recorded by the Investigator and defined as AECOPD that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Number · exacerbation per participant-year
Annualized Rate of Severe COPD Exacerbations Over the 52-Week Treatment Period
exacerbation per participant-yearPlaceboDupilumab 300 mg q2w
Annualized Rate of Severe COPD Exacerbations Over the 52-Week Treatment Period0.086 (0.050 to 0.147)0.072 (0.040 to 0.132)
SecondaryTime to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period

The time to first moderate or severe exacerbation was defined as date of the first event minus randomization date +1. The median time to first severe exacerbation was derived from Cox regression model. Moderate exacerbations events were recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days.

Time frame:
Baseline (Day 1) and up to Weeks 12, 24, 36 and 52
Reported as:
Median · weeks
Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period
weeksPlaceboDupilumab 300 mg q2w
Up to Week 120.019 (0.009 to 0.035)0.024 (0.013 to 0.041)
Up to Week 240.039 (0.024 to 0.059)0.034 (0.021 to 0.054)
Up to Week 360.045 (0.029 to 0.067)0.039 (0.024 to 0.059)
Up to Week 520.061 (0.042 to 0.086)0.043 (0.027 to 0.065)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An Adverse Event (AE) was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TE period which was defined as the period from the time of first dose of study treatment until the last visit in the study. Serious adverse events (SAE) were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

Time frame:
TEAEs were collected from the time from the first administration of study treatment to the last administration of the study treatment + 98 days, up to 491 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboDupilumab 300 mg q2w
Any TEAE359365
Any TESAE7465
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA) to Dupilumab

Number of participants with treatment-emergent response to dupilumab with peak post-baseline titers during the on-treatment period are reported. Treatment-emergent response was defined as a positive response in the ADA assay post first dose, when baseline results were negative or missing. Categories were based on titer values and included: low (Titer \<1000); moderate (1000\<=Titer\<=10,000); and high (Titer \>10,000). On-treatment period was defined as last study treatment administration plus 14 days; that is, Week 52.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA) to Dupilumab
ParticipantsPlaceboDupilumab 300 mg q2w
Low titer727
Moderate titer01
High titer02

Adverse events

Collected over TEAEs were collected from the time from the first administration of study treatment to the last administration of the study treatment + 98 days, up to 491 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo9/470 (1.9%)74/470 (15.7%)172/470 (36.6%)
Dupilumab 300 mg q2w8/469 (1.7%)65/469 (13.9%)168/469 (35.8%)
Most frequent serious events
Showing 10 of 124
Most frequent serious events
EventPlaceboDupilumab 300 mg q2w
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders26/47028/469
PneumoniaInfections and infestations12/4706/469
Covid-19 PneumoniaInfections and infestations5/4702/469
Covid-19Infections and infestations4/4703/469
Lower Respiratory Tract InfectionInfections and infestations2/4703/469
Respiratory FailureRespiratory, thoracic and mediastinal disorders3/4701/469
Cerebral HaemorrhageNervous system disorders0/4702/469
Cardiac FailureCardiac disorders2/4702/469
Coronary Artery DiseaseCardiac disorders1/4702/469
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders2/4702/469
Most frequent other events
Most frequent other events
EventPlaceboDupilumab 300 mg q2w
Upper Respiratory Tract InfectionInfections and infestations46/47037/469
NasopharyngitisInfections and infestations45/47045/469
HeadacheNervous system disorders33/47038/469
Accidental OverdoseInjury, poisoning and procedural complications30/47026/469
HypertensionVascular disorders28/47017/469
DiarrhoeaGastrointestinal disorders17/47025/469
Back PainMusculoskeletal and connective tissue disorders16/47025/469

Baseline characteristics

The Randomized population consisted of any participant who was allocated to a randomized treatment regardless of whether the treatment kit was used.

Age, Continuous
Age, Continuous(years)PlaceboDupilumab 300 mg q2wTotal
Median65.2 ± 8.165.0 ± 8.065.1 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumab 300 mg q2wTotal
Female149170319
Male322298620
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDupilumab 300 mg q2wTotal
American Indian or Alaska Native437
Asian6767134
Native Hawaiian or Other Pacific Islander101
Black or African American235
White397393790
More than one race022
Unknown or Not Reported000
08

Study locations

275 sites
  • SEC Clinical Research, LLC-Site Number:8400030
    Andalusia, Alabama 36420, United States
  • Clinical Research Center of Alabama, LLC-Site Number:8400041
    Birmingham, Alabama 35209-6802, United States
  • UAB Lung Health Center-Site Number:8400013
    Birmingham, Alabama 35294, United States
  • SEC Clinical Research, LLC-Site Number:8400059
    Dothan, Alabama 36303, United States
  • Pulmonary Associates of Mobile, P.C.-Site Number:8400057
    Mobile, Alabama 36608, United States
  • Asthma and Allergy Associates, PC-Site Number:8400034
    Colorado Springs, Colorado 80907, United States
  • Clinical Research Of West Florida Inc-Site Number:8400010
    Clearwater, Florida 33765, United States
  • Finlay Medical Research-Site Number:8400014
    Greenacres City, Florida 33467, United States
  • Project 4 research, Inc.-Site Number:8400023
    Miami, Florida 33125, United States
  • Finlay Medical Research-Site Number:8400062
    Miami, Florida 33126, United States
  • Renstar Medical Research-Site Number:8400051
    Ocala, Florida 34470, United States
  • Florida Institute for Clinical Research, LLC-Site Number:8400029
    Orlando, Florida 32825, United States
  • Emerald Coast Research Associates-Site Number:8400032
    Panama City, Florida 32405, United States
  • Sarasota Clinical Research-Site Number:8400026
    Sarasota, Florida 34239, United States
  • VitaLink research-Hamilton Mill-Site Number:8400055
    Dacula, Georgia 30019, United States
  • DC Research Works-Site Number:8400016
    Marietta, Georgia 30060, United States
  • North Georgia Clinical Research-Site Number:8400025
    Woodstock, Georgia 30189, United States
  • Johns Hopkins University (Asthma and Allergy Center)-Site Number:8400012
    Baltimore, Maryland 21224, United States
  • Asthma Allergy & Sinus Center-Site Number:8400038
    White Marsh, Maryland 21162, United States
  • Michigan Medicine (University of Michigan)-Site Number:8400050
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic Lanmark Center 2-46-Site Number:8400065
    Rochester, Minnesota 55905, United States
  • Midwest Chest Consultants, P.C.-Site Number:8400011
    Saint Charles, Missouri 63301, United States
  • Washington University School of Medicine-Site Number:8400004
    Saint Louis, Missouri 63104, United States
  • Sierra Clinical Research-Site Number:8400035
    Las Vegas, Nevada 89106, United States
  • Va Western New York Healthcare-Site Number:8400067
    Buffalo, New York 14215, United States
  • IMA Clinical Research, LLC-Site Number:8400070
    New York, New York 10036, United States
  • The University of North Carolina at Chapel Hill - Division of Pulmonary and Critical Care Medicine-Site Number:8400019
    Chapel Hill, North Carolina 27514, United States
  • American Health Research-Site Number:8400061
    Charlotte, North Carolina 28277, United States
  • Duke Asthma, Allergy and Airway Center-Site Number:8400064
    Durham, North Carolina 27705, United States
  • Accellacare-Site Number:8400052
    Wilmington, North Carolina 28401, United States
  • Southeastern Research Center-Site Number:8400060
    Winston-Salem, North Carolina 27103-4027, United States
  • Midwest Pulmonary and Sleep Research Center-Site Number:8400040
    Dayton, Ohio 45459, United States
  • Aventiv Research, Inc-Site Number:8400024
    Dublin, Ohio 43016, United States
  • OK Clinical Research-Site Number:8400005
    Edmond, Oklahoma 73034, United States
  • Velocity Clinical Research, Medford-Site Number:8400001
    Medford, Oregon 97504, United States
  • Jefferson Associates in Internal Medicine-Site Number:8400037
    Clairton, Pennsylvania 15025, United States
  • Temple University Hospital-Site Number:8400009
    Philadelphia, Pennsylvania 19140, United States
  • Emphysema COPD Research Center, Kaufmann Medical Building-Site Number:8400033
    Pittsburgh, Pennsylvania 15213, United States
  • Berks Schuylkill Respiratory Specialists, LTD-Site Number:8400063
    Wyomissing, Pennsylvania 19610, United States
  • VitaLink Research-Easley-Site Number:8400022
    Easley, South Carolina 29640, United States
  • VitaLink Research- Gaffney-Site Number:8400047
    Gaffney, South Carolina 29340, United States
  • VitaLink Research-Greenville-Site Number:8400007
    Greenville, South Carolina 29615, United States
  • Clinical Research of Charleston-Site Number:8400044
    Mount Pleasant, South Carolina 29464, United States
  • Clinical Research of Rock Hill-Site Number:8400046
    Rock Hill, South Carolina 29732, United States
  • VitaLink Research - Spartanburg-Site Number:8400048
    Spartanburg, South Carolina 29303, United States
  • Clinical Trials Center of Middle Tennessee-Site Number:8400073
    Franklin, Tennessee 37067, United States
  • Bayer College of Medicine-Site Number:8400018
    Houston, Texas 77030, United States
  • Metroplex Pulmonary and Sleep Center-Site Number:8400021
    McKinney, Texas 75069, United States
  • Sherman Clinical Research-Site Number:8400027
    Sherman, Texas 75092, United States
  • MultiCare Institute for Research and Innovation-Site Number:8400036
    Tacoma, Washington 98405, United States
  • Allergy, Asthma & Sinus Center, S.C.-Site Number:8400008
    Greenfield, Wisconsin 53228, United States
  • Investigational Site Number :0320011
    Caba, Buenos Aires 1430, Argentina
  • Investigational Site Number :0320002
    Caba, Buenos Aires C1414AIF, Argentina
  • Investigational Site Number :0320003
    Caba, Buenos Aires C1425BEN, Argentina
  • Investigational Site Number :0320004
    Caba, Buenos Aires C1425FVH, Argentina
  • Investigational Site Number :0320012
    La Plata, Buenos Aires B1900BNN, Argentina
  • Investigational Site Number :0320007
    Quilmes, Ciudad De Buenos Aires B1878FNR, Argentina
  • Investigational Site Number :0320006
    Rosario, Santa Fe S2000DBS, Argentina
  • Investigational Site Number :0320009
    San Miguel de Tucumán, Tucumán T4000IAR, Argentina
  • Investigational Site Number :0320001
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number :0320005
    Buenos Aires, Argentina
  • Investigational Site Number :0320008
    Mar Del Plata, B7600, Argentina
  • Investigational Site Number :0320010
    Mendoza, 5500, Argentina
  • Investigational Site Number :1001004
    Haskovo, 6305, Bulgaria
  • Investigational Site Number :1001003
    Montana, 3400, Bulgaria
  • Investigational Site Number :1001006
    Ruse, 7002, Bulgaria
  • Investigational Site Number :1001009
    Sofia, 1202, Bulgaria
  • Investigational Site Number :1001002
    Sofia, 1233, Bulgaria
  • Investigational Site Number :1001001
    Sofia, 1680, Bulgaria
  • Investigational Site Number :1001005
    Stara Zagora, 6001, Bulgaria
  • Investigational Site Number :1001010
    Troyan, 5600, Bulgaria
  • Investigational Site Number :1240021
    Edmonton, Alberta T5H4B9, Canada
  • Investigational Site Number :1240015
    Edmonton, Alberta T6G 2G3, Canada
  • Investigational Site Number :1240016
    Sherwood Park, Alberta T8H 0N2, Canada
  • Investigational Site Number :1240017
    Vancouver, British Columbia V5Z 1M9, Canada
  • Investigational Site Number :1240007
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Investigational Site Number :1240002
    Burlington, Ontario L7N 3V2, Canada
  • Investigational Site Number :1240012
    Toronto, Ontario M5T 3A9, Canada
  • Investigational Site Number :1240013
    Windsor, Ontario N8X 5A6, Canada
  • Investigational Site Number :1240009
    Montreal, Quebec H1M 1B1, Canada
  • Investigational Site Number :1240003
    Montreal, Quebec H1T 1C8, Canada
  • Investigational Site Number :1240001
    Montreal, Quebec H4A 3J1, Canada
  • Investigational Site Number :1240010
    Sherbrooke, Quebec J1H 5N4, Canada
  • Investigational Site Number :1240011
    Sherbrooke, Quebec J1L 0H8, Canada
  • Investigational Site Number :1240006
    St-charles Borrommee, Quebec J6E 2B4, Canada
  • Investigational Site Number :1240008
    Trois-Rivieres, Quebec G8T 7A1, Canada
  • Investigational Site Number :1240020
    Victoriaville, Quebec G6P 6P6, Canada
  • Investigational Site Number :1240005
    Quebec, G1V 4G5, Canada
  • Investigational Site Number :1240004
    Quebec, G1V 4W2, Canada
  • Investigational Site Number :1240019
    Quebec, G3K 2P8, Canada
  • Investigational Site Number :1240018
    Quebec, GIS 2L6, Canada
  • Investigational Site Number :1520006
    Curicó, Maule 3341643, Chile
  • Investigational Site Number :1520001
    Talca, Maule, Chile
  • Investigational Site Number :1520009
    Santiago, Reg Metropolitana De Santiago 7500587, Chile
  • Investigational Site Number :1520003
    Santiago, Reg Metropolitana De Santiago 7500692, Chile
  • Investigational Site Number :1520005
    Santiago, Reg Metropolitana De Santiago 7500698, Chile
  • Investigational Site Number :1520008
    Santiago, Reg Metropolitana De Santiago 8380453, Chile
  • Investigational Site Number :1520002
    Santiago, Reg Metropolitana De Santiago 8910131, Chile
  • Investigational Site Number :1520004
    Quillota, Valparaíso 2260877, Chile
  • Investigational Site Number :1560037
    Baotou, 014010, China

Showing the first 100 of 275 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Feb 2023, 45 months.

Results were first posted in Feb 2024, 1 year after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 45 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2019
First posted
Apr 29, 2019
StartActual
Apr 15, 2019
Primary completionActual
Feb 8, 2023
CompletionActual
May 2, 2023
Results first posted
Feb 28, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03930732
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 29, 2019
Start date
Apr 15, 2019
Primary completion
Feb 8, 2023
Completion
May 2, 2023
Results posted
Feb 28, 2024
Last update
Feb 28, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion